Загрузка...
Management of patients with advanced non-small cell lung cancer: role of gefitinib
Gefitinib is the first epidermal growth factor receptor tyrosine-kinase inhibitor approved for the treatment of advanced non-small cell lung cancer (NSCLC). Its failure to improve survival in a placebo-control study, however, led to its withdrawal in the United States though it is available in many...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2880342/ https://ncbi.nlm.nih.gov/pubmed/20531966 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|